Harris Labs, Neo-Pharm acquisitions by Canada's MDS Health Group will push CRO sales over C$100 mil.
HARRIS LABS ACQUISITION BY MDS HEALTH GROUP and the MDS purchase of Neo-Pharm Labs will more than double MDS' annual pharmaceutical sciences revenue stream to over C$100 mil., the Toronto-based firm said Aug. 20. Total MDS annual sales were C$689 mil. in FY 1995 (ended March 31). Toronto-based MDS is Canada's largest technology-based health and life sciences firm, the company said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth